桑志培 博士 副教授 博士/硕士生导师 海南自由贸易港高层次人才

 邮箱：sangzhipei@hainanu.edu.cn

 1.教育背景及工作经历

 2022.08-至今 伟德bv1946官网，副教授

 2021.11-至今 上海中医药大学，交叉科学研究院，博士后

 2019-05至2020-06，新加坡南洋理工大学，生物科学学院，博士后

 2010-09至2015-06，四川大学华西伟德bv1946官网，硕博连读

 2006-09至2010-07，贵州医科大学，药学，学士

 2.科研情况

 目前研究方向聚焦于“基于靶向磷酸二酯酶（PDEs）和/或丝氨酸水解酶的全新药物设计、结构优化、成药性评价及作用机制研究”。主持国家自然科学基金、海南省自然科学基金高层次人才项目、中国博士后科学基金面上项目等8项基金，并在Eur J Med Chem, Anal Chem, Plant Cell, Bioorg Chem, J Agric Food Chem等学术期刊发表论文100余篇,其中以第一或/和通讯作者发表SCI论文47篇（中科院一区12篇，二区14篇）；出版英文专著2部；已授权国家发明专利27项（转让1项），实用新型专利5项。

3.研究领域

基于天然活性小分子的全新药物分子设计、结构和成药性优化及作用机制研究。

4.社会兼职

《Chinese Chemical Letters》(中国化学快报）第四届青年编委会委员

《Frontiers in Pharmacology》期刊的Topic Editors

5.代表性项目

(1) 国家自然科学基金地区基金，“选择性丁酰胆碱酯酶抑制剂的设计、类药性优化及抗AD作用机制研究”，2024.01-2027.12，主持

(2) 海南省自然科学基金高层次人才项目，“丁酰胆碱酯酶选择性抑制剂的合理设计、成药性优化及抗阿尔茨海默症作用研究”，2024.01-2025.12，主持

(3) BV伟德国际1946科研启动基金项目，“靶向PDE4的新型抗AD药物研究”，2022.09-2026.12，主持

(4) 中国博士后科学基金第71批面上项目二等资助，“人羧酸酯酶2A特异性共价抑制剂的设计研发、成药性优化及药效学研究”，2022.01-2023.12，主持。

(5) 贵州医科大学 省部共建药用植物功效与利用国家重点实验室开放课题，“杜仲中新型多肽的制备及其活性评价”，2022.01-2023.12，主持。

(6) 贵州医科大学 化学合成药物研发利用工程技术研究中心开放课题，“具有诱导自噬作用的cGN14细胞穿膜环肽的设计、合成及其抗AD活性研究”，2021.08-2022.07，主持。

(7) 河南省科技厅科技攻关项目，“裕丹参中新型多肽的发现及药理活性研究”，2021.01-2022.12，主持

(8) 2020年河南省高等学校重点科研项目，“基于脑靶向的新型高选择性BuChE抑制剂的设计、合成及其抗阿尔茨海默病活性研究”，2020.01-2021.12，主持

(9) 2019年河南省高层次人才国际化培养项目，“口服植物活性肽的研究”，2019.05-2020.06，主持

(10) 河南省自然科学基金，“基于Aβ/AChE双靶点策略的查尔酮衍生物的设计、合成与抗阿尔茨海默病活性研究”，2016.01-2017.12，主持

(11) 2017年河南省高等学校重点科研项目计划，“新型多靶点抑制剂的设计、合成及抗阿尔茨海默症活性研究”，2017.01-2018.12，主持

6.代表性成果（#表示为共同第一，*表示为通讯作者）

(1) Zhipei Sang^#,*, Ya Zhang^#, Hairong Zeng^#, Yunqing Song^#, Xin-Rui Guo^#, Guanghao Zhu, Changhai Luan, Zhengwei Liu, Mengqi Huang, Zhenhui Su, Xinjuan Li, Dapeng Chen^*, Shuheng Huang^*, Guang-Bo Ge^*. Intelligent drug design and development of highly specific and efficacious hCES2A inhibitors for ameliorating irinotecan-induced gut toxicity. Nature Communications, 2024 (Under review) (IF = 17)

(2) Ya Zhang^#, Guang-Hao Zhu^#, Yun-Qing Song^#, Xin-Juan Li^#, Xin-Rui Guo, Hong-Xin Li, Xiao-Yu Zhuang, Ya-Ni Zhang, Meng-Ru Sun, Jian Huang^*, Da-Peng Chen^*, Zhi-Pei Sang^*, Guang-Bo Ge^*. Discovery of novel donepezil-fused chalcones as orally available, potent and selective covalent inhibitors against hCES2A for alleviating irinotecan-induced gut toxicity. Science Advances, 2024 (Under review) (IF = 15.4)

(3) Chen Rui^#, Li Xinjuan^#, Chen Hongsong^#, Wang Keren^#, Xue Teng, Mi Jing, Ban Yujuan, Zhu Gaofeng, Zhou Yi, Dong Wu^*, Tang Lei^*, Sang Zhipei^*. Development of the “hidden” multi-target-directed ligands by AChE/BuChE for the treatment of Alzheimer’s disease. European Journal of Medicinal Chemistry. 2023, 251: 115253.(IF=7.088)

(4) Chen Hongsong^#, Mi Jing^#, Li Sen^#, Liu Zhengwei, Yang Jing, Chen Rui, Wang Yujie, Ban Yujuan, Zhou Yi^*, Dong Wu^*, Sang Zhipei^*.Design, synthesis and evaluation of quinoline-O-carbamate derivatives as multifunctional agents for the treatment of Alzheimer's disease.Journal of Enzyme Inhibition and Medicinal Chemistry. 2023, 38(1): 2169682. (IF = 5.756)

(5) Zhou Yi^#, He Ying^#, Xue Teng^#, Mi Jing, Yang Jing, Wei Rongrui, Liu Wenmin^*, Ma Qinge^*, Tan Zhenghuai^*, Sang Zhipei^*. Development of novel salicylic acid-donepezil-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer's disease. Journal of Enzyme Inhibition and Medicinal Chemistry. 2023, 38(1): 2231661. (IF = 5.756)

(6) The sources, properties, extraction, biosynthesis, pharmacology, and application of lycopene. Wei RR, Lin QY, Adu M, Huang HL, Yan ZH, Shao F, Zhong GY, Zhang ZL^*, Sang ZP^*, Cao L^*, Ma QG^*. Food & Function. 2023, 14(22): 9974-9998.   (IF = 6.1)

(7) Rationally Engineered hCES2A Near-Infrared Fluorogenic Substrate for Functional Imaging and High-Throughput Inhibitor Screening. Fan Y, Zhang T, Song Y, Sang Z, Zeng H, Liu P, Wang P, Ge G. Analytical Chemistry. 2023, 95(42): 15665-15672. (IF = 7.4)

(8) Ma Qinge^*, Chen Jie, Chen Lihua, Wu Guang, Zhu Meining, He Nengxin, Wang Qinyuan, Sang Zhipei^*, Zhu Caiqing, Wu Yongzhong, Wei Rongrui^*. Citrus medica var. Sarcodactylus (Siebold ex Hoola van Nooten) Swingle: an insight into its botany, traditional uses, phytochemistry, and pharmacological properties. Phytochemistry Reviews. 2023, April 06, https://doi.org/10.1007/s11101-023-09865-0. (IF = 7.41)

(9) Ma Qinge, He Nengxin, Huang Huilian, Fu Xiaomei, Zhang Zhongli, Shu Jicheng, Wang Qinyuan, Chen Jie, Wu Guang, Zhu Meining, Sang Zhipei^*, Cao Lan^*, Wei Rongrui^*. Hippophae rhamnoides L.: A Comprehensive Review on the Botany, Traditional Uses, Phytonutrients, Health Benefits, Quality Markers, and Applications. Journal of Agricultural and Food Chemistry. 2023, 71(12): 4769-4788. (IF = 5.895)

(10) Sang Zhipei^#,*, Bai Ping^#, Ban Yujuan^#, Wang Kerne^#, Wu Anguo, Mi Jing, Hu Jiaqi, Xu Rui, Zhu Gaofeng, Wang Jianta, Zhang Jiquan, Wang Changning^*, Tan Zhenghuai^*, Tang Lei^*. Novel donepezil-chalcone-rivastigmine hybrids as potential multifunctional anti-Alzheimer's agents: Design, synthesis, in vitro biological evaluation, in vivo and in silico studies. Bioorganic Chemistry. 2022, 127: 106007. (IF = 5.307)

(11) Liu Chan^#, Sang Zhipei^#, Pan Hong, Wu Qin, Qiu Yu^*, Shi Jingshan^*. A novel multifunctional 5,6-dimethoxy-indanone-chalcone-carbamate hybrids alleviates cognitive decline in Alzheimer's disease by dual inhibition of acetylcholinesterase and inflammation. Frontiers in Aging Neuroscience. 2022, 14: 922650.(IF = 5.702)

(12) Side Hu, Abbas EI Sahili, Srujana Kishore, Yee Hwa Wong, Xinya Hemu, Boon Chong Goh, Zhipei Sang, Zhen Wang, James P Tam, Chuan-Fa Liu, Julien Lescar. Structural basis for proenzyme maturation, substrate recognition, and ligation by a hyperactive peptide asparaginyl ligase. Plant Cell. 2022, 34(12): 4936-4949. (IF = 12.085)

(13) Zhou XG, Qiu WQ, Yu L, Pan R, Teng JF, Sang ZP, Law BY, Zhao Y, Zhang L, Yan L, Tang Y, Sun XL, Wong VKW, Yu CL, Wu JM, Qin DL, Wu AG. Targeting microglial autophagic degradation of the NLRP3 inflammasome for identification of thonningianin A in Alzheimer's disease. Inflammation Regeneration. 2022, 42(1): 25. (IF = 10.426)

(14) Ma Qinge, Guan Yang, Sang Zhipei^*, Dong Jianghong, Wei Rongrui^*. Isolation and characterization of auronlignan derivatives with hepatoprotective and hypolipidemic activities from the fruits of Hippophae rhamnoides L. Food & Function. 2022, 13(14):7750-7761. (IF = 6.317)

(15) Sang Zhipei^#,*, Wang Keren^#, Dong Jianghong^#, Tang Lei^*. Alzheimer's disease: Updated multi-targets therapeutics are in clinical and in progress. European Journal of Medicinal Chemistry. 2022, 238: 114464. (IF = 7.088)

(16) Zhu Gaofeng^#, Bai Ping^#, Wang Keren^#, Mi Jing, Yang Jing, Hu Jiaqi, Ban Yujuan, Xu Rui, Chen Rui, Wang Changning^*, Tang Lei^*, Sang Zhipei^*. Design, synthesis, and evaluation of novel O-alkyl ferulamide derivatives as multifunctional ligands for treating Alzheimer's disease. Journal of Enzyme Inhibition and Medicinal Chemistry. 2022, 37(1): 1375-1388. (IF = 5.756)

(17) Yang Jing^#, Zhou Yi^#, Ban Yujuan^#, Mi Jing, He Ying, Li Xinjuan, Liu Zhengwei, Wang Keren, Zhu Gaofeng, Liu Wenmin, Tan Zhenghuai^*, Sang Zhipei^*. Development of naringenin-O-alkylamine derivatives as multifunctional agents for the treatment of Alzheimer’s disease. Journal of Enzyme Inhibition and Medicinal Chemistry. 2022, 37(1): 792-816. (IF = 5.756)

(18) Sang Zhipei, Song Qing, Cao Zhongcheng, Deng Yong, Zhang Li^*. Design, synthesis, and evaluation of chalcone-Vitamin E-donepezil hybrids as multi-target-directed ligands for the treatment of Alzheimer's disease. Journal of Enzyme Inhibition and Medicinal Chemistry. 2022, 37(1): 69-85. (IF = 5.756)

(19) Wang Keren^#, Shi Jian^#, Zhou Yi, He Ying, Mi Jing, Yang Jing, Liu Shuang, Tang Xiangcheng, Liu Wenmin, Tan Zhenghuai^*, Sang Zhipei^*. Design, synthesis and evaluation of cinnamic acid hybrids as multi-target-directed agents for the treatment of Alzheimer’s disease. Bioorganic Chemistry. 2021, 112：104879. (IF = 5.307)

(20) Sang Zhipei^*,#, Song Qing, Cao Zhongcheng, Deng Yong, Tan Zhenghuai, Zhang Li^*. Design, synthesis and evaluation of novel dimethylamino chalcone-O-alkylamines derivatives as potential multifunctional agents against Alzheimer's disease. European Journal of Medicinal Chemistry. 2021, 216: 113310. (IF = 7.088)

(21) Sang Zhipei^*,#, Shi Jian^#, Zhou Yi, Wang Keren, Zhao Yiyang, Li Qingfeng, Qiao Zhanpin, Wu Anguo^*, Tan Zhenghuai^*, Liu Wenmin^*. Development of genistein-O-alkylamines derivatives as multifunctional agents for the treatment of Alzheimer's disease. Bioorganic Chemistry. 2021, 107: 104602. (IF = 5.307)

(22) Sang Zhipei^*,#, Wang Keren^#, Bai Ping^#, Wu Anguo, Shi Jian, Wenmin Liu, Zhu Gaofeng, Wang Yiling, Lan Yu, Chen Zude, Zhao Yiyang, Zhanpin Qiao, Wang Changning^*, Tan Zhenghuai^*. Design, synthesis and biological evaluation of novel O-carbamoyl ferulamide derivatives as multi-target-directed ligands for the treatment of Alzheimer's disease. European Journal of Medicinal Chemistry, 2020, 194: 112265. (IF = 6.514)

(23) Sang Zhipei^*,#, Wang Keren^#, Shi Jian, Wenmin Liu, Cheng xinfeng, Zhu Gaofeng, Wang Yiling, Zhao Yiyang, Zhanpin Qiao, Wu Anguo^*, Tan Zhenghuai^*. The development of advanced structural framework as multi-target-directed ligands for the treatment of Alzheimer’s disease. European Journal of Medicinal Chemistry, 2020, 192: 112180. (IF = 6.514)

(24) Sang Zhipei^*,#, Wang Keren^#, Shi Jian, Cheng xinfeng, Zhu Gaofeng, Wei Rongrui, Ma Qinge, Yu Lintao, Zhao Yiyang, Tan Zhenghuai^*, Liu Wenmin^*. Apigenin-rivastigmine hybrids as multi-target-directed ligands for the treatment of Alzheimer’s disease. European Journal of Medicinal Chemistry, 2020, 187: 111958. (IF = 6.514)

(25) Sang Zhipei^*,#, Wang Keren^#, Zhang Pengfei, Shi Jian, Liu Wenmin^*, Tan Zhenghuai^*. Design, synthesis, in-silico and biological evaluation of novel chalcone derivatives as multi-function agents for the treatment of Alzheimer’s disease. European Journal of Medicinal Chemistry, 2019, 180: 238-252. (IF = 5.573)

(26) Sang Zhipei^*,#, Wang Keren^#, Shi Jian, Liu Wenmin^*, Tan Zhenghuai^*. Design, synthesis, in-silico and biological evaluation of novel chalcone-O-carbamate derivatives as multifunctional agents for the treatment of Alzheimer’s disease. European Journal of Medicinal Chemistry, 2019, 178: 726-739. (IF = 5.573)

(27) Bai Ping^#, Wang Keren^#, Zhang Pengfei^#, Shi Jian, Cheng Xinfeng, Zhang Qi, Zheng Cheng, Yang Jian, Lu Xiaoxia^*, Sang Zhipei^*. Development of chalcone-O-alkylamine derivatives as multifunctional agents against Alzheimer’s disease. European Journal of Medicinal Chemistry, 2019, 183: 111737. ( IF = 5.573)

(28) Sang Zhipei^*,#, Wang Keren^#, Han Xue, Cao Mengxiao, Tan Zhenghuai^*, Liu Wenmin^*. Design, synthesis and evaluation of novel ferulic acid derivatives as multi-target-directed ligands for the treatment of Alzheimer's disease. ACS Chemical Neuroscience. 2019, 10(2): 1008-1024. (IF = 4.486)

(29) Sang Zhipei^*, Pan Wanli, Wang Keren, Ma Qinge, Yu Lintao, Yang Yan, Bai Ping, Leng Chaoliang, Xu Qian, Li Xiaoqing, Tan Zhenghuai, Liu Wenmin^*. Design, synthesis and evaluation of novel ferulic acid-O-alkylamine derivativesas potential multifunctional agents for the treatment of Alzheimer’s disease. European Journal of Medicinal Chemistry, 2017, 130: 379-392. (IF = 4.816)

(30) Sang Zhipei ^#, Qiang Xiaoming ^#, Li Yan, Xu Rui, Xu Zhongcheng, Song Qing, Wang Ting, Zhang Xiaoyu, Liu Hongyan, Tan Zhenghuai^*, Deng Yong^*. Design, synthesis and evaluation of scutellarein-O-acetamidoalkylbenzylamines as potential multifunctional agents for the treatment of Alzheimer's disease. European Journal of Medicinal Chemistry, 2017, 135: 307-323. (IF = 4.816)

2016年之前发表代表性文章

(1) Wanli Pan, Ke Hu, Ping Bai, Lintao Yu, Qinge Ma, Tao Li, Xu Zhang, Chaozhong Chen, Kelin Peng, Wenmin Liu^*, Zhipei Sang ^*. Design, synthesis and evaluation of novel ferulic acid-memoquin hybrids as potential multifunctional agents for the treatment of Alzheimer’s disease. Bioorganic & Medicinal Chemistry Letters. 2016, 26(10): 2539-2543. (IF = 2.454)

(2) Zhipei Sang, Xiaoming Qiang, Yan Li, Wen Yuan, Qiang Liu, Wei Ang, Yikun Shi, Youfu Luo, Zhenhuai Tan^*, Yong Deng^*, Design, synthesis and evaluation of scutellarein-O-alkylamines as potent multifunctional anti-Alzheimer’s disease agents for the treatment of Alzheimer's disease. European Journal of Medicinal Chemistry, 2015, 94: 348-366. (IF = 3.902)

(3) Zhipei Sang, Xiaoming Qiang, Yan Li, Bei Wu, Hui Zhang, Minggao Zhao, Yong Deng^*, Design, synthesis and biological evaluation of scutellarein carbamate derivatives as potential multifunctional agents for the treatment of Alzheimer's disease. Chemical Biology & Drug Design, 2015, 86(5): 1168-1177. (IF = 2.485)

(4) Zhipei Sang, Yan Li, Xiaoming Qiang, Ganyuan Xiao, Qiang Liu, Zhenhuai Tan^*, Yong Deng^*, Multifunctional scutellarin-rivastigmine hybrids with cholinergic, antioxidant, biometals chelating and neuroprotective properties for the treatment of Alzheimer's disease. Bioorganic & Medicinal Chemistry, 2015, 23(4): 668-680. (IF = 2.793)

(5) Xiaoming Qiang^#, Zhipei Sang^#, Wen Yuan, Yan Li, Qiang Liu, Ping Bai, Yikun Shi, Wei Ang, Zhenhuai Tan^*, Yong Deng^*, Design, synthesis and evaluation of genistein-O-alkylbenzylamines as potential multifunctional agents for the treatment of Alzheimer's disease. European Journal of Medicinal Chemistry, 2014, 76: 314-331. (IF = 3.343)

已授权代表性发明专利

(1) 桑志培; 王柯人；柳文敏；时健；程新峰；于林涛. 一种2’-羟基-3苯基苯丙酮化合物及其制备方法和用途. 2022.01.07. 中国 ZL2019106197603.

(2) 桑志培; 王柯人; 柳文敏; 于林涛; 时健; 马倩文; 王慧娟.一种茚酮查尔酮氨基甲酸酯类化合物及其制备方法和用途. 2021.03.30. 中国ZL2019101892884.

(3) 桑志培; 王柯人; 柳文敏; 于林涛; 时健; 程新峰；马倩文. 一种4-氨基甲酸酯-肉桂酰胺-4-苄基哌啶类化合物及其制备方法和用途. 2020.11.03. 中国ZL2019100795872.

(4) 桑志培; 王柯人; 柳文敏; 程新峰; 时健; 于林涛; 冉亚文. 一种芹菜素-O-烷基胺类化合物、制备方法和应用. 2020.06.26. 中国ZL2019100960136.

(5) 桑志培; 柳文敏; 王柯人; 潘万里; 张胜; 程新峰. 一种N-(4-苄基哌啶基)-阿魏酰胺化合物、制备方法及其用途. 2019.06.18. 中国 ZL2017100584209

7. 荣誉奖励

(1) 2020年度河南省教育厅科技成果奖优秀科技论文奖二等奖，河南省教育厅，教科技[2020]135号, 2020.05，第一

(2) 第十五届“挑战杯”河南省老员工课外学术科技作品竞赛中荣获“二等奖”两项，2021.06，第一指导教师

(3) 第十三届“挑战杯”河南省老员工课外学术科技作品竞赛二等奖，2017.08.10，第一指导教师

(4) 第八届“国药工程—东富龙杯”全国老员工制药工程设计竞赛二等奖，2018.08，第二指导教师

欢迎有药学、生物学、化学等相关学科背景的同学报考本课题组的博士/硕士研究生。

（2024年度还有博士招生名额）